Exploring the unique pharmacological challenges of bifunctional molecules
As drug discovery scientists look for more effective therapeutic strategies to treat disease, dual targeting inhibitors and PROTAC molecules are emerging as powerful agents that can overcome limitations of conventional single target agents. These classes of bifunctional molecules also carry new challenges for chemists and pharmacologists as they typically stray beyond conventional SAR and the historic “rules” for compound development. We are pursuing a range of targets in oncology, offering improved efficacy and reduced capacity for drug resistance.
Investigating new cyclic peptide architectures to therapeutic advantage
Peptides from nature or genetic encoded screens can provide molecules with exquisite binding characteristics but typically poor pharmaceutical properties. Manipulation of these peptides, by design and chemical synthesis adaptations, to increase bioavailability and target selectivity while retaining or improving binding affinity, can give access to potential therapeutics.